Paula Lum, MD, MPH

Professor

Paula J. Lum, MD MPH is Professor of Clinical Medicine and founding Program Director of the UCSF Primary Care Addiction Medicine Fellowship. She has been a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at San Francisco General Hospital since 1999. Board certified in internal medicine and addiction medicine, Dr. Lum practices at the places where HIV, addiction, and poverty collide. Her research and clinical activities are grounded in evidence-based, patient-centered care to improve the health and well-being of the urban poor. Her current areas of focus include: (1) HIV and viral hepatitis prevention and treatment in persons who use drugs, (2) evidence-based interventions in primary care and non-traditional settings for unhealthy substance use and its complications, and (3) curricular interventions to provide health care professionals with the skills, knowledge, and confidence to offer effective patient-centered care to persons who use drugs.
Education
2019 - Diversity, Equity, and Inclusion Champion Training, University of California, San Francisco
Fellowship, 1999 - AIDS Prevention Studies, University of California, San Francisco
M.P.H., 1997 - Epidemiology, University of California, Berkeley
Residency, 1996 - Primary Care Internal Medicine, SFGH, University of California, San Francisco
M.D., 1993 - Medicine, Case Western Reserve University
B.A., 1985 - Human Biology, Stanford University
M.A., 1985 - Sociology, Stanford University
Honors and Awards
  • Meg Newman Award for Teaching Excellence, UCSF Division of HIV, Infectious Diseases & Global Medicine, 2024
  • John Murray Award for Academic Excellence and Dedication to the Mission of San Francisco General, San Francisco General Hospital Medical Services, 2021
  • W. Anderson Spickard, Jr. Excellence in Mentorship Award, Association for Multidisciplinary Education and Research in Substance use and Addiction (AMERSA), 2019
  • Norman E. Zinberg Award for Achievement in the Field of Medicine, Drug Policy Alliance, 2019
  • Chancellor Award for Public Service, Faculty Nominee, University of California, San Francisco, 2018
  • Alpha Omega Alpha Honor Medical Society, Faculty Nominee, UCSF Chapter of AOA’s Class of 2011, 2011
  • Excellence in Direct Teaching and/or Excellence in Mentoring and Advising Award, Haile T. Debas Academy of Medical Educators, UCSF School of Medicine, 2007
  • Outstanding Teacher and Distinguished Lecturer Award, UCSF Division of HIV/AIDS at San Francisco General Hospital, 2000
  • Janet M. Glasgow Memorial Achievement Citation, American Medical Women’s Association, 1993
  • Alpha Omega Alpha Honor Medical Society, Case Western Reserve University School of Medicine, 1993
Websites
Publications

  1. Snehal S. Lopes, J. Edward Dotherow, Irene Pericot-Valverde, Paula J. Lum, Lynn E. Taylor, Shruti H. Mehta, Judith I. Tsui, Judith Feinberg, Arthur Y. Kim, Brianna L. Norton, Kimberly Page, Cristina Murray-Krezan, Jessica Anderson, Alison Karasz, Julia Arnsten, Phillip Moschella, Moonseong Heo, Alain H. Litwin, the HERO study group. Patient-Navigator Working Alliance and Hepatitis C Treatment Cascade Outcomes Among Persons Who Inject Drugs: The HERO Study. 2025. PMID:


  2. Obeysekare J, Pericot-Valverde I, Lopes S, Groome M, Norton BL, Tsui JI, Mehta SH, Taylor LE, Lum PJ, Feinberg J, Kim AY, Page K, Heo M, Litwin AH, HERO Study Group. Improvement in anxiety symptoms during treatment of Hepatitis C in people who inject drugs: The HERO study. 2025. PMID: 39999625


  3. Bhatraju EP, Tsui JI, Heo M, Sivaraj LB, Lopes SS, Mehta S, Lum P, Taylor LE, Feinberg J, Kim A, Norton B, Pericot-Valverde I, Page KA, Litwin AH. Interest in Injectable and Oral PrEP for HIV Prevention Among Women and Men Who Inject Drugs. 2025. PMID: 39846474


  4. Tsui JI, Ludwig-Barron NT, James JR, Heo M, Sivaraj LB, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Falade-Nwulia O, Feinberg J, Kim AY, Norton B, Page K, Litwin AH. Current Self-reported Pain Before and After Cure of Hepatitis C Among Persons Who Actively Inject Drugs. 2024. PMID: 39475112


  5. Lopes SS, Heo M, Pericot-Valverde I, Norton BL, Taylor LE, Tsui JI, Mehta SH, Feinberg J, Kim AY, Lum PJ, Page K, Murray-Krezan C, Anderson J, Litwin AH. Variability of Hepatitis C Treatment Cascade Outcomes among People Who Inject Drugs across Geographically Diverse Clinics in the US: The HERO Study. 2024. PMID: 39459883


  6. Litwin AH, Tsui JI, Heo M, Mehta SH, Taylor LE, Lum PJ, Feinberg J, Kim AY, Norton BL, Pericot-Valverde I, Arnsten J, Meissner P, Karasz A, McKee MD, Ward JW, Johnson N, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Carty J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Groome M, Davies S, Costello K, Page K, HERO Study Group. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study. 2024. PMID: 39186268


  7. Lopes SS, Pericot-Valverde I, Dotherow JE, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH, HERO study group. Effect of self-efficacy among persons who inject drugs treated with direct-acting antivirals on Hepatitis C treatment initiation, duration, completion, adherence, and cure. 2024. PMID: 38991632


  8. Elenore Bhatraju, Judith Tsui, Andrea C. Radick, Moonseong Heo, Laksika Sivaraj, Shruti H Mehta, Paula Lum, Lynn Taylor, Judith Feinberg, Arthur Kim, Brianna Norton, Irene Pericot-Valverde, Kimberly Page, Alain Litwin. EXPLORATION OF HIV RISK BEHAVIORS AND ATTITUDES TOWARDS PREP AMONG PEOPLE WHO INJECT DRUGS BY GENDER AND SEXUAL ORIENTATION. 2024. PMID:


  9. Fokuo JK, Hutman PJ, Gruber VA, Masson CL, Lum PJ, Bush DM, Naugle JA, Sorensen JL. Substance use Attitudes, Beliefs, Experience, and Knowledge Among Nursing and Nursing Assistant Students. 2024. PMID: 38646910


  10. Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. 2024. PMID: 38395747


  11. Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten J, Sprecht-Walsh S, Page K, Litwin AH, HERO Study Group, National Stakeholder Advisory Board. Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study. 2024. PMID: 38242324


  12. Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Moschella P, Heo M, Litwin AH. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study. 2023. PMID: 38103458


  13. Batchelder AW, Heo M, Foley JD, Sullivan MC, Lum P, Pericot Valverde I, Taylor LE, Mehta SH, Kim AY, Norton B, Tsui JI, Feinberg J, Page K, Litwin AH, HERO Study Group. Shame and stigma in association with the HCV cascade to cure among people who inject drugs. 2023. PMID: 37951006


  14. Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, Tsui JI, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A, HERO Research Group. Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study. 2023. PMID: 38023556


  15. Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, Tsui JI, Wagner K, Litwin A. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences. 2023. PMID: 37266986


  16. Tsui JI, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH, HERO Study Group. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. 2023. PMID: 37150144


  17. Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K, HERO Study Group. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. 2022. PMID: 36370741


  18. Korthuis PT, Cook RR, Lum P, Waddell EN, Tookes H, Vergara-Rodriguez P, Kunkel LE, Lucas GM, Rodriguez A, Bielavitz S, Fanucchi L, Hoffman K, Bachrach K, Payne EH, Collins JA, Matthews A, Oden N, Jacobs P, Jelstrom E, Sorensen JL, McCarty D. HIV Clinic-Based Extended Release Naltrexone versus Treatment as Usual for People with HIV and Opioid Use Disorder: A Non-Blinded, Randomised Non-inferiority Trial. 2022. PMID: 35129242


  19. Perera R, Stephan L, Appa A, Giuliano R, Hoffman R, Lum P, Martin M. Meeting people where they are: implementing hospital-based substance use harm reduction. 2022. PMID: 35139877


  20. Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. 2021. PMID: 34758887


  21. Cook RR, Torralva R, King C, Lum PJ, Tookes H, Foot C, Vergara-Rodriguez P, Rodriguez A, Fanucchi L, Lucas GM, Waddell EN, Korthuis PT. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. 2021. PMID: 34600253


  22. Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WO, Forman M, Thomas E, Thornton K, Wagner K, Vassilev V, Lin L, Lum PJ, Giudice LC, Stein E, Asher A, Chang S, Gorman R, Ghany MG, Liang TJ, Wierzbicki MR, Scarselli E, Nicosia A, Folgori A, Capone S, Cox AL. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. 2021. PMID: 33567193


  23. Hagle HN, Martin M, Winograd R, Merlin J, Finnell DS, Bratberg JP, Gordon AJ, Johnson C, Levy S, MacLane-Baeder D, Northup R, Weinstein Z, Lum PJ. Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addiction. 2021. PMID: 33465013


  24. Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. 2021. PMID: 34176462


  25. Martin M, Snyder HR, Coffa D, Steiger S, Clement JP, Ranji SR, Azari S, Nguyen OK, Lum PJ. Time to ACT: launching an Addiction Care Team (ACT) in an urban safety-net health system. 2021. PMID: 33500326


  26. Hoffman KA, Baker R, Kunkel LE, Waddell EN, Lum PJ, McCarty D, Korthuis PT. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. 2019. PMID: 31752905


  27. Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, Tsui JI, Pericot-Valverde I, Page K. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. 2019. PMID: 31669450


  29. Satterfield JM, Gregorich SE, Kalkhoran S, Lum PJ, Bloome J, Alvarado N, Muñoz RF, Vijayaraghavan M. Computer-Facilitated 5A's for Smoking Cessation: A Randomized Trial of Technology to Promote Provider Adherence. 2018. PMID: 29929682


  30. Mirzazadeh A, Evans JL, Hahn JA, Jain J, Briceno A, Shiboski S, Lum PJ, Bentsen C, Davis G, Shriver K, Dimapasoc M, Stone M, Busch MP, Page K. Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement. 2018. PMID: 29168067


  31. Hettema JE, Cockrell SA, Reeves A, Ingersoll KS, Lum PJ, Saitz R, Murray-Krezan CM, Carrejo VA. Development and differentiability of three brief interventions for risky alcohol use that include varying doses of motivational interviewing. 2018. PMID: 29482632


  32. Page K, Cox A, Lum PJ. Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. 2018. PMID: 29320280


  33. Dawson-Rose C, Draughon JE, Cuca Y, Zepf R, Huang E, Cooper BA, Lum PJ. Changes in Specific Substance Involvement Scores among SBIRT recipients in an HIV primary care setting. 2017. PMID: 29229000


  34. Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P. 2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus. 2017. PMID: 29091230


  36. Kalkhoran S, Alvarado N, Vijayaraghavan M, Lum PJ, Yuan P, Satterfield JM. Patterns of and reasons for electronic cigarette use in primary care patients. 2017. PMID: 28710596


  37. Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. 2017. PMID: 28628854


  38. Vijayaraghavan M, Yuan P, Gregorich S, Lum P, Appelle N, Napoles AM, Kalkhoran S, Satterfield J. Disparities in receipt of 5As for smoking cessation in diverse primary care and HIV clinics. 2017. PMID: 28271025


  39. Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sorensen JL, Arenas V, Ha D, Mandler RN, McCarty D. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. 2017. PMID: 28061017


  40. Todd Korthuis, Paula J. Lum, P. Vergara-Rodriguez, Keith Ahamad, Evan Wood, R. Lindblad, Raul Mandler, James Sorensen, Doan Ha, Neal Oden, Lynn Kunkel, Dennis McCarty. Extended-release naltrexone feasibility in HIV clinics: A pilot study. 2017. PMID:


  41. Ahamad K, Korthuis PT, Lum PJ, Johnson C, Wood E. A delayed injection-site reaction in a patient receiving extended-release naltrexone. 2016. PMID: 26820699


  42. Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, Page K. A Longitudinal Study of Multiple Drug Use and Overdose Among Young People Who Inject Drugs. 2016. PMID: 26985620


  43. Paula J. Lum, R. Douglas Bruce. Comorbid substance use among persons with HIV and chronic pain. 2016. PMID:


  44. Dawson-Rose C, Draughon JE, Zepf R, Cuca YP, Huang E, Freeborn K, Lum PJ. Prevalence of Substance Use in an HIV Primary Care Safety Net Clinic: A Call for Screening. 2015. PMID: 26763795


  45. Elise Riley, Judith A. Hahn, Jennifer L. Evans, Alya Briceno, Peter J. Davidson, Paula J. Lum, Kimberly Page. The longitudinal influence of multiple depressant use on nonfatal overdose among young people who inject drugs. 2015. PMID:


  46. Kalkhoran S, Appelle NA, Napoles AM, Munoz RF, Lum PJ, Alvarado N, Gregorich SE, Satterfield JM. Beyond the Ask and Advise: Implementation of a Computer Tablet Intervention to Enhance Provider Adherence to the 5As for Smoking Cessation. 2015. PMID: 26150093


  47. Dawson Rose C, Cuca YP, Kamitani E, Eng S, Zepf R, Draughon J, Lum P. Using Interactive Web-Based Screening, Brief Intervention and Referral to Treatment in an Urban, Safety-Net HIV Clinic. 2015. PMID: 25963770


  48. Soraya Azari, Neda Ratanawongsa, Jennifer Hettema, Caroline Cangelosi, Matt Tierney, Diana Coffa, Brad Shapiro, Sharad Jain, David Hersh, Jennifer Manuel, Daniel Ciccarone, Paula Lum. A Skills-Based Curriculum for Teaching Motivational Interviewing-Enhanced Screening, Brief Intervention, and Referral to Treatment (SBIRT) to Medical Residents. 2015. PMID:


  52. Ratanawongsa N, Barton JL, Schillinger D, Yelin EH, Hettema JE, Lum PJ. Ethnically diverse patients' perceptions of clinician computer use in a safety-net clinic. 2013. PMID: 24185151


  53. McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. 2013. PMID: 24118434


  54. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. Interactions between alcohol and the HIV entry inhibitor Maraviroc. 2013. PMID: 23881910


  55. McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. 2013. PMID: 23666322


  56. Sara M. Buckelew, Amy Whittle, Paula Lum, Patricia O'Sullivan, Jason M. Satterfield. 8. Implementing Sbirt in Pediatrics: Results of a Needs Assessment. 2013. PMID:


  58. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, Delwart E, Tobler L, Cox AL, Busch MP. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. 2012. PMID: 23090930


  59. McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. Untreated HIV infection is associated with higher blood alcohol levels. 2012. PMID: 22495786


  60. Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. 2012. PMID: 22227793


  61. Hettema JE, Ratanawongsa N, Manuel JK, Ciccarone D, Coffa D, Jain S, Lum PJ. A SBIRT curriculum for medical residents: development of a performance feedback tool to build learner confidence. 2012. PMID: 22738001


  62. Johnson MO, Dilworth SE, Stephens E, Lum PJ, Neilands TB. Expectancy and readiness-based predictors of treatment uptake among the urban poor living with HIV. 2011. PMID: 21926630


  63. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. 2011. PMID: 21810243


  65. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. 2011. PMID: 21317592


  66. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. 2011. PMID: 21317590


  67. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. 2011. PMID: 21317600


  68. Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, Fiellin DA. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. 2011. PMID: 21317601


  69. Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, Fiellin DA. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. 2011. PMID: 21317595


  70. Etcheverry MF, Lum PJ, Evans JL, Sanchez E, de Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. 2011. PMID: 21241735


  71. Rose CD, Courtenay-Quirk C, Knight K, Shade SB, Vittinghoff E, Gomez C, Lum PJ, Bacon O, Colfax G. HIV intervention for providers study: a randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. Volume 55 of Issue 5. 2010. PMID: 20827218


  72. Levy V, Evans JL, Stein ES, Davidson PJ, Lum PJ, Hahn JA, Page K. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? 2010. PMID: 20638453


  73. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. 2010. PMID: 20491725


  74. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch MP. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. 2009. PMID: 19764883


  76. Inglez-Dias A, Hahn JA, Lum PJ, Evans J, Davidson P, Page-Shafer K. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. 2008. PMID: 18368610


  77. Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. 2008. PMID: 18233994


  78. Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. 2007. PMID: 17980513


  80. Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. 2007. PMID: 17197817


  82. Bacon O, Lum P, Hahn J, Evans J, Davidson P, Moss A, Page-Shafer K. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Volume 33 of Issue 4. 2006. PMID: 16565643


  83. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. 2006. PMID: 16340470


  84. W. Kittikraisak, P. J. Davidson, J. A. Hahn, P. J. Lum, J. L. Evans, A. R. Moss, K. Page-Shafer. Incarceration among young injectors in San Francisco: associations with risk for hepatitis C virus infection. 2006. PMID:


  85. Lum PJ, Sears C, Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. 2005. PMID: 16253934


  86. Paula J. Lum, Kristen C. Ochoa, Judith A. Hahn, Kimberly Page Shafer, Jennifer L. Evans, Andrew R. Moss. LUM
    ET AL.
    RESPOND.     2004. PMID:


  87. Lum PJ, Ochoa KC, Hahn JA, Page Shafer K, Evans JL, Moss AR. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. 2003. PMID: 12773355


  88. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, Moss AR. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). 2003. PMID: 12612103


  89. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. 2002. PMID: 12447014


  90. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. 2002. PMID: 12447730


  91. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. 2001. PMID: 11431749